Synlogic Appoints Dr. Aoife Brennan as President and Chief Executive Officer

From Startup Synlogic Tx

Link to Full Article:

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Oct. 2, 2018–
Synlogic, Inc. (Nasdaq:
SYBX), a clinical stage company applying synthetic biology to
probiotics to develop novel, living medicines, today announced the
appointment of Aoife Brennan, M.B., B.Ch., as president and chief
executive officer of Synlogic, effective immediately. Dr. Brennan joined
Synlogic as chief medical officer in 2016 and has served as interim
president and chief executive officer since May 2018.

“After conducting a thorough search process, it was clear to the board
of directors that Aoife is the right person to lead Synlogic at this
time in the company’s evolution,” said Peter Barrett, chairman of
Synlogic’s board of directors. “Aoife stepped into the interim role and
rapidly demonstrated her effectiveness. Her broad experience across
multiple stages of drug development and therapeutic areas, her
demonstrated leadership abilities, and her ambitious vision for
Synlogic, make her uniquely qualified for the job. We are confident that
under her leadership, Synlogic will be well-positioned to deliver
Synthetic Biotic™ medicines to patients.”

“I appreciate the confidence and support of the board of directors and
am thrilled to be selected to lead Synlogic as we pioneer the
development of a completely new class of living medicines,” said Dr.
Brennan. “We have made great progress to date, advancing two Synthetic
BioticTM programs into the clinic. I look forward to
continuing to execute on our plans for the clinical development of our
lead candidates while capitalizing on the broad applicability and
potential of our novel platform to build a pipeline of therapies for
patients with serious and life-threatening diseases.”

Prior to joining Synlogic, Dr. Brennan spent six years at Biogen in
roles of increasing responsibility, most recently as vice president and
head of the Rare Disease Innovation Unit, which included programs
ranging from pre-clinical to commercial. She has also led programs
across multiple therapeutic areas including the late-phase development
of nusinersen for spinal muscular atrophy and treatments for Hemophilia
B and Hemophilia A, ALPROLIX® and ELOCTATE®.
Earlier, Dr. Brennan was director of clinical development at Tolerx, a
start-up biotech company focused on immunotherapy for Type 1 diabetes.
Dr. Brennan holds a medical degree from Trinity College Dublin, Ireland
and completed her post-graduate training in internal medicine,
endocrinology and metabolism at the Royal College of Physicians in
Ireland. Additionally, she completed post-doctoral training in clinical
research and metabolism at the Beth Israel Deaconess Medical Center in
Boston and is a graduate of the Harvard Medical School Scholars in
Clinical Science Program.

About SynlogicSynlogic is pioneering the development of a
novel class of living medicines, Synthetic Biotic medicines, based on
its proprietary drug development platform. Synlogic leverages the tools
and principles of synthetic biology to genetically engineer probiotic
microbes to perform or deliver critical functions missing or damaged due
to disease. The company’s two lead programs, SYNB1020 and SYNB1618,
target hyperammonemia as a result of liver damage or genetic disease,
and PKU, respectively. When delivered orally, Synthetic Biotic medicines
can act from the gut to compensate for the dysfunctional metabolic
pathway and have a systemic effect, with the potential to significantly
improve symptoms of disease for affected patients. In addition, the
company is leveraging the broad potential of its platform to create
Synthetic Biotic medicines for the treatment of more common diseases,
including liver disease, inflammatory and immune disorders, and cancer.
Synlogic is collaborating with AbbVie to develop Synthetic Biotic-based
treatments for inflammatory bowel disease (IBD). For more information,
please visit

Forward-Looking StatementsThis press release contains
“forward-looking statements” that involve substantial risks and
uncertainties for purposes of the safe harbor provided by the Private
Securities Litigation Reform Act of 1995. All statements, other than
statements of historical facts, included in this press release regarding
strategy, future operations, future financial position, future revenue,
projected expenses, prospects, plans and objectives of management are
forward-looking statements. In addition, when or if used in this press
release, the words “may,” “could,” “should,” “anticipate,” “believe,”
“estimate,” “expect,” “intend,” “plan,” “predict” and similar
expressions and their variants, as they relate to Synlogic may identify
forward-looking statements. Examples of forward-looking statements,
include, but are not limited to, statements regarding the potential of
Synlogic’s platform to develop therapeutics to address a wide range of
diseases including: inborn errors of metabolism, liver disease,
inflammatory and immune disorders, and cancer; the future clinical
development of Synthetic Biotic medicines; the approach Synlogic is
taking to discover and develop novel therapeutics using synthetic
biology; the potential of Synlogic’s technology to treat hyperammonemia
and phenylketonuria; and the expected timing of Synlogic’s anticipated
clinical trial initiations. Actual results could differ materially from
those contained in any forward-looking statement as a result of various
factors, including: the uncertainties inherent in the preclinical
development process; the ability of Synlogic to protect its intellectual
property rights; and legislative, regulatory, political and economic
developments, as well as those risks identified under the heading “Risk
Factors” in Synlogic’s filings with the SEC. The forward-looking
statements contained in this press release reflect Synlogic’s current
views with respect to future events. Synlogic anticipates that
subsequent events and developments will cause its views to change.
However, while Synlogic may elect to update these forward-looking
statements in the future, Synlogic specifically disclaims any obligation
to do so. These forward-looking statements should not be relied upon as
representing Synlogic’s view as of any date subsequent to the date

View source version on
Source: Synlogic
SynlogicMEDIA CONTACT:Courtney Heath,
617-872-2462courtney@scientpr.comorINVESTOR CONTACT:Elizabeth
Wolffe, Ph.D.,

Please visit their site for more information: Synlogic

All,Biotechnology,Healthcare News
2018-10-03 04:43:40